

Maurie Markman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/325832/publications.pdf>

Version: 2024-02-01

169
papers

12,017
citations

101543

36
h-index

25787

108
g-index

390
all docs

390
docs citations

390
times ranked

17166
citing authors

#	ARTICLE	IF	CITATIONS
1	Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2015, 8, 466-471.	0.7	4,609
2	Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 1001-1007.	1.6	993
3	Ovarian cancer. <i>Lancet, The</i> , 2009, 374, 1371-1382.	13.7	594
4	Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 2460-2465.	1.6	447
5	Somatic Mutations in <i>BRCA1</i> and <i>BRCA2</i> Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3570-3576.	1.6	342
6	Ethical Conflict in Providing Informed Consent for Clinical Trials: A Problematic Example from the Gynecologic Cancer Research Community. <i>Oncologist</i> , 2004, 9, 3-7.	3.7	334
7	Clinical Features of Hypersensitivity Reactions to Carboplatin. <i>Journal of Clinical Oncology</i> , 1999, 17, 1141-1141.	1.6	320
8	Second-Line Treatment of Ovarian Cancer. <i>Oncologist</i> , 2000, 5, 26-35.	3.7	277
9	Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1460-1466.	1.6	243
10	Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design. <i>Journal of Clinical Oncology</i> , 2004, 22, 3120-3125.	1.6	211
11	Intraperitoneal antineoplastic drug delivery: rationale and results. <i>Lancet Oncology, The</i> , 2003, 4, 277-283.	10.7	208
12	Phase II trial of weekly paclitaxel (80 mg/m ²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006, 101, 436-440.	1.4	205
13	Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 988-994.	1.6	171
14	Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. <i>Journal of Clinical Oncology</i> , 2000, 18, 102-102.	1.6	168
15	The Use of Paclitaxel and Platinum-Based Chemotherapy in Uterine Papillary Serous Carcinoma. <i>Gynecologic Oncology</i> , 1999, 74, 272-277.	1.4	154
16	Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions. <i>Drug Safety</i> , 2001, 24, 767-779.	3.2	152
17	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1992, 45, 284-289.	1.4	151
18	Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity. <i>Journal of Clinical Oncology</i> , 2003, 21, 4611-4614.	1.6	142

#	ARTICLE	IF	CITATIONS
19	Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175Åmg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. <i>Gynecologic Oncology</i> , 2009, 114, 195-198.	1.4	126
20	Managing taxane toxicities. <i>Supportive Care in Cancer</i> , 2003, 11, 144-147.	2.2	125
21	Toxicities of the platinum antineoplastic agents. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 597-607.	2.4	121
22	Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, 593-596.	1.4	110
23	Pharmaceutical Management of Ovarian Cancer. <i>Drugs</i> , 2008, 68, 771-789.	10.9	95
24	Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum. <i>Journal of Clinical Oncology</i> , 2001, 19, 1901-1905.	1.6	80
25	Epithelial ovarian cancer in the elderly: The memorial sloan-kettering cancer center experience. <i>Cancer</i> , 2010, 71, 634-637.	4.1	64
26	Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. <i>Gynecologic Oncology</i> , 2004, 93, 699-701.	1.4	59
27	Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. <i>Gynecologic Oncology</i> , 2006, 100, 133-138.	1.4	59
28	An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 427-429.	2.5	56
29	Management of toxicities associated with the administration of taxanes. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 141-146.	2.4	54
30	Intraperitoneal Drug Delivery of Antineoplastics. <i>Drugs</i> , 2001, 61, 1057-1065.	10.9	49
31	Pharmaceutical Management of Ovarian Cancer: Current Status. <i>Drugs</i> , 2019, 79, 1231-1239.	10.9	49
32	Safety issues in using complementary and alternative medicine. <i>Journal of Clinical Oncology</i> , 2002, 20, 39S-41S.	1.6	49
33	Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 515-519.	8.7	47
34	Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 25-28.	2.5	46
35	An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3615-3620.	1.6	45
36	Tumor chemosensitivity and chemoresistance assays. , 1996, 77, 1020-1025.		39

#	ARTICLE	IF	CITATIONS
37	Viewing ovarian cancer as a "chronic disease": What exactly does this mean?. <i>Gynecologic Oncology</i> , 2006, 100, 229-230.	1.4	39
38	The Role of CA-125 in the Management of Ovarian Cancer. <i>Oncologist</i> , 1997, 2, 6-9.	3.7	39
39	Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action. <i>Journal of Clinical Oncology</i> , 2007, 25, 4168-4170.	1.6	38
40	Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2003, 91, 573-576.	1.4	37
41	Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2000, 77, 112-115.	1.4	36
42	Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 390-393.	1.4	35
43	Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m ² over 3 h) employed in the treatment of gynecologic malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 55-58.	2.5	31
44	Chemoradiation in the Management of Cervix Cancer: Current Status and Future Directions. <i>Oncology</i> , 2013, 84, 246-250.	1.9	31
45	Optimizing primary chemotherapy in ovarian cancer. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 957-968.	2.2	28
46	Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 697-698.	2.5	27
47	Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 241-245.	1.4	27
48	Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , 2004, 94, 404-408.	1.4	22
49	New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer. <i>Oncologist</i> , 2007, 12, 186-190.	3.7	22
50	Optimal Management of Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, S40-S43.	2.5	22
51	Maintenance chemotherapy in the management of epithelial ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 11-17.	5.9	22
52	Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. <i>Gynecologic Oncology</i> , 2019, 154, 420-425.	1.4	21
53	When Regulatory Requirements Conflict with Ethical Study Design: The Case of Oral Ondansetron. <i>Cancer Investigation</i> , 1994, 12, 654-656.	1.3	20
54	Advances in cervical cancer pharmacotherapies. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 219-223.	3.1	20

#	ARTICLE	IF	CITATIONS
55	Chronic Administration of Single-Agent Paclitaxel in Gynecologic Malignancies. <i>Gynecologic Oncology</i> , 2001, 81, 201-205.	1.4	18
56	Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. <i>Gynecologic Oncology</i> , 2004, 92, 180-182.	1.4	17
57	Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum. <i>Oncology</i> , 2004, 66, 343-346.	1.9	16
58	An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 105-109.	2.0	16
59	Role of Intraperitoneal Chemotherapy in the Front-Line Setting. <i>Journal of Clinical Oncology</i> , 2003, 21, 145s-148.	1.6	14
60	Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. <i>Cancer Management and Research</i> , 2011, 3, 219-25.	1.9	13
61	HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E103-8.	1.4	13
62	Intraperitoneal Chemotherapy in the Treatment of Ovarian Cancer. <i>Annals of Medicine</i> , 1996, 28, 293-296.	3.8	12
63	A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 26-30.	2.5	12
64	Cyclophosphamide-Induced Severe Acute Hyponatremic Encephalopathy in Patients with Breast Cancer: Report of Two Cases. <i>Case Reports in Oncology</i> , 2014, 7, 550-554.	0.7	12
65	Self-forgiveness is associated with reduced psychological distress in cancer patients and unmatched caregivers: Hope and self-blame as mediating mechanisms. <i>Journal of Psychosocial Oncology</i> , 2017, 35, 544-560.	1.2	12
66	Cardiotoxicity of Antineoplastic Agents: What Is the Present and Future Role for Imaging?. <i>Current Oncology Reports</i> , 2014, 16, 396.	4.0	11
67	Intraperitoneal Therapy of Ovarian Cancer. <i>Oncologist</i> , 1996, 1, 18-21.	3.7	11
68	The dangers of "cross-trial" and "cross-retrospective experience" comparisons. <i>Cancer</i> , 2007, 109, 1929-1932.	4.1	10
69	Antiangiogenic drugs in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2269-2277.	1.8	10
70	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 45-47.	2.7	10
71	Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer: Efficacy, Toxicity, and Future Directions. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 169-173.	0.8	10
72	Challenges associated with evaluating the clinical utility of non-cytotoxic pharmaceutical agents in oncology. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 581-582.	2.5	9

#	ARTICLE	IF	CITATIONS
73	Limitations to the use of the CA-125 antigen level in ovarian cancer. <i>Current Oncology Reports</i> , 2003, 5, 263-264.	4.0	9
74	Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: Time for an evidence-based comparison. <i>Gynecologic Oncology</i> , 2010, 118, 6-7.	1.4	9
75	Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 121-124.	4.9	9
76	Cardio-Oncology: mechanisms of cardiovascular toxicity. <i>F1000Research</i> , 2018, 7, 113.	1.6	9
77	Carboplatin and cisplatin: are they equivalent in efficacy in ?optimal residual? advanced ovarian cancer?. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 443-444.	2.5	8
78	Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 224-226.	2.5	8
79	Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. <i>Gynecologic Oncology</i> , 2003, 91, 118-122.	1.4	8
80	Informing patients with cancer of ?new findings? that may influence their willingness to participate in research studies. <i>Cancer</i> , 2003, 98, 885-887.	4.1	8
81	Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2004, 95, 109-113.	1.4	8
82	Serious Ethical Dilemma of Single-Agent Pegylated Liposomal Doxorubicin Employed As a Control Arm in Ovarian Cancer Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, e319-e320.	1.6	8
83	Commentary: Implications of Cancer Managed as a "Chronic Illness". <i>Current Oncology Reports</i> , 2011, 13, 90-91.	4.0	8
84	Information Overload in Oncology Practice and its Potential Negative Impact on the Delivery of Optimal Patient Care. <i>Current Oncology Reports</i> , 2011, 13, 249-251.	4.0	8
85	Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 715-717.	1.4	7
86	Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. <i>Women's Health</i> , 2018, 14, 174550571775069.	1.5	7
87	Is There a Role for Intraperitoneal Therapy in the Management of Gastrointestinal Malignancies?. <i>Cancer Investigation</i> , 1995, 13, 625-628.	1.3	6
88	Limits to the "Benefits" from Our Oncologic Interventions: A Case Report. <i>Gynecologic Oncology</i> , 2000, 78, 261-262.	1.4	6
89	The needs of science vs the needs of patients: ethical concerns in cancer clinical trials.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, 1008-1009.	1.3	6
90	Second-line chemotherapy for refractory cancer: Intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 1994, 10, 299-304.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports. <i>Gynecologic Oncology</i> , 2002, 86, 95-98.	1.4	5
92	Consolidation/maintenance chemotherapy for ovarian cancer. <i>Current Oncology Reports</i> , 2003, 5, 454-458.	4.0	5
93	Can We Do a Better Job Preventing Clinically-Relevant Peripheral Neuropathy Resulting from Carboplatin/Paclitaxel Chemotherapy?. <i>Cancer Investigation</i> , 2004, 22, 471-473.	1.3	5
94	Taxanes in the management of gynecologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 219-226.	2.4	5
95	Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation. <i>Case Reports in Oncology</i> , 2018, 10, 840-845.	0.7	5
96	The importance of distinguishing "Clinical Judgement" in cancer management from "selection bias" in clinical trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 573-574.	2.5	4
97	Clinical response versus clinical benefit in oncology: not necessarily equivalent terms. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 363-364.	2.5	4
98	Is it good clinical judgment or selection bias?. <i>Current Oncology Reports</i> , 2001, 3, 377-378.	4.0	4
99	Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process. <i>Cancer</i> , 2003, 98, 215-218.	4.1	4
100	The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 628-629.	4.3	4
101	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 124, 171.	1.4	4
102	Pegylated Liposomal Doxorubicin-Induced Acute Transient Encephalopathy in a Patient with Breast Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2014, 7, 228-232.	0.7	4
103	Genomic-Based Therapy of Gynecologic Malignancies. <i>Acta Medica Academica</i> , 2019, 48, 84.	0.8	4
104	Rationale for maintenance or consolidation therapy in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 176-8.	0.3	4
105	Prolonged Disease-Free and Treatment-Free Survival in Platinum-Resistant Ovarian Cancer Following Extended (> 1 Year) Administration of Single-Agent Paclitaxel: A Case Report and Discussion of Potential Clinical Implications. <i>Cancer Investigation</i> , 2005, 23, 33-35.	1.3	3
106	An Example of Ovarian Cancer as a "Chronic Disease Process" - 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease. <i>Case Reports in Oncology</i> , 2008, 1, 1-4.	0.7	3
107	Presentation of Chemotherapy Options for Cervix Cancer on Cancer-Related Internet Sites. <i>Journal of Women's Health</i> , 2009, 18, 827-829.	3.3	3
108	Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. <i>Gynecologic Oncology</i> , 2011, 122, 213-214.	1.4	3

#	ARTICLE	IF	CITATIONS
109	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?. <i>Oncologist</i> , 2016, 21, 529-531.	3.7	3
110	Clinical response versus clinical benefit in oncology: not necessarily equivalent terms. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 243-244.	2.5	2
111	Surgical staging of cancer: Impact on prognosis and potential for bias in clinical trials. <i>Current Oncology Reports</i> , 2003, 5, 437-438.	4.0	2
112	Second-line chemotherapy of epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 31-36.	2.4	2
113	The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy. <i>Cancer</i> , 2011, 117, 660-661.	4.1	2
114	Mutations and non-inferiority analyses show a way forward. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 69-70.	27.6	2
115	Metastatic Breast Cancer with Extensive Osseous Metastasis Presenting with Symptomatic Immune Thrombocytopenic Purpura and Anemia: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2015, 8, 256-263.	0.7	2
116	Optimism and the continued promise of maintenance chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 879-880.	2.3	2
117	The Evolving Arena of Ovarian Cancer Maintenance Therapy. <i>Oncology</i> , 2019, 97, 202-205.	1.9	2
118	Clinical practice guidelines in oncology: pros and cons. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 381-382.	2.5	1
119	The administration of paclitaxel without prophylaxis for the prevention of hypersensitivity reactions: is this a rationale and safe therapeutic strategy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 531-532.	2.5	1
120	Monitoring and Improving Quality of Cancer Care: Easy to Recommend, Difficult to Accomplish. <i>Cancer Investigation</i> , 2001, 19, 96-97.	1.3	1
121	Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology. <i>Cancer</i> , 2007, 109, 1003-1006.	4.1	1
122	Involvement of Bone in Epithelial Ovarian Cancer: Case Report of an Uncommon Late Metastatic Event. <i>Case Reports in Oncology</i> , 2011, 4, 490-491.	0.7	1
123	Ovarian Cancer Survival: Steady Improvement, Despite Rhetoric to the Contrary. <i>Current Oncology Reports</i> , 2013, 15, 433-435.	4.0	1
124	Management of Cancer in the Elderly: An Essential Need for More Clinically Relevant Data. <i>Oncology</i> , 2013, 85, 166-167.	1.9	1
125	Challenging the Requirements for Disclosing Risk to Clinical Research Participants. <i>American Journal of Bioethics</i> , 2014, 14, 11-12.	0.9	1
126	A Case Report Demonstrating the Potential Clinical Relevance of Liquid Tumor Biopsies in Lung Cancer. <i>Case Reports in Oncology</i> , 2017, 9, 714-717.	0.7	1

#	ARTICLE	IF	CITATIONS
127	The Requirement for Increasingly Effective Societal Cancer Control Efforts. <i>Current Oncology Reports</i> , 2018, 20, 9.	4.0	1
128	Lenvatinib Real-Life Experience. <i>Oncology</i> , 2019, 97, 189-190.	1.9	1
129	New developments in the anti-neoplastic drug management of ovarian cancer. <i>F1000prime Reports</i> , 2013, 5, 48.	5.9	1
130	HPV vaccination as a strategy for cancer prevention. <i>Future Virology</i> , 2020, 15, 67-70.	1.8	1
131	Are we winning or losing the war on cancer?. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, 632-633.	1.3	1
132	Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, 368-369.	1.3	1
133	Genetic discrimination arising from cancer risk assessments: a societal dilemma.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 12-12.	1.3	1
134	Update on the utility of prognostic biomarkers in ovarian cancer. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	1
135	Precision Cancer Medicine. <i>MD Advisor: A Journal for New Jersey Medical Community</i> , 2018, 11, 4-6.	0.0	1
136	Clinical response versus clinical benefit in oncology: not necessarily equivalent terms. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 363-364.	2.5	1
137	Lapatinib as a therapeutic option in brain metastases from HER2+ breast cancer. <i>Annals of Palliative Medicine</i> , 2013, 2, 35-6.	1.2	1
138	Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolved. <i>Journal of Cancer Research and Clinical Oncology</i> , 1998, 124, 1-3.	2.5	0
139	A phase 2 study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1998, 124, 353-353.	2.5	0
140	Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies? A Response to the Essay from Dr. Eddie Reed. <i>Cancer Investigation</i> , 1998, 16, 142-143.	1.3	0
141	Cisplatin/Epinephrine Injectable Gel. <i>Drugs and Aging</i> , 2001, 18, 794-795.	2.7	0
142	Response to: "Establishing evidence for change in ovarian cancer surgery" Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis (Chua TC, et al.) <i>Gynecologic Oncology</i> , 2009, 115, 168.	1.4	0
143	The Myth of Measurable Disease in Ovarian Cancer: Revisited. <i>Cancer Investigation</i> , 2009, 27, 11-12.	1.3	0
144	Bypassing phase 1 trials in the cancer drug development paradigm: Generally unwise and potentially dangerous. <i>Cancer</i> , 2010, 116, 5116-5118.	4.1	0

#	ARTICLE	IF	CITATIONS
145	Combination Cytotoxic and Antiangiogenic Therapy in the Management of Epithelial Ovarian Cancer. Combination Products in Therapy, 2011, 1, 1.	1.1	0
146	Abandoning "TAP" as Treatment of Metastatic Endometrial Cancer: A Serious Example of the Consequences Resulting from the Failure To Adequately Define the Question Being Addressed in a Phase 3 Trial. Current Oncology Reports, 2012, 14, 480-482.	4.0	0
147	Provider Impact on Survival Outcomes in the Management of Malignant Disease. Current Oncology Reports, 2013, 15, 193-196.	4.0	0
148	Continuation or Reintroduction of an Antineoplastic Strategy after Documented Disease Progression. Oncology, 2013, 85, 348-349.	1.9	0
149	Surgical Aspects of Thoracic Malignancies. , 2014, , 711-718.		0
150	Early-Stage Esophageal and Stomach Cancers. , 2014, , 553-561.		0
151	Dangers of "Confirmatory" Cancer Trials That Fail To Actually Test the Original Hypothesis. Current Oncology Reports, 2014, 16, 381.	4.0	0
152	External Beam Radiation with "Curative Intent" in Advanced Ovarian Cancer: An Uncommon but Rational Management Approach Based on the Natural History of Cancer in an Individual Patient. Oncology, 2014, 86, 230-231.	1.9	0
153	An Experience with Managing Cancer Patients Reportedly Previously Informed of the Absence of Additional Available Antineoplastic Therapeutic Options. Case Reports in Oncology, 2014, 7, 633-637.	0.7	0
154	Cancer Care Institutions and Advertising. JAMA Internal Medicine, 2016, 176, 1877.	5.1	0
155	Prevention of a Sexually Transmitted Disease versus Prevention of a Serious Female Cancer: Remarkably Divergent Views of HPV Vaccination. Women's Health, 2016, 12, 83-85.	1.5	0
156	Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies. Women's Health, 2016, 12, 396-399.	1.5	0
157	Case of Ovarian Cancer in a Woman with Undiagnosed Graves' Disease: A Case Report and Review of the Literature. Case Reports in Oncology, 2017, 10, 452-454.	0.7	0
158	Progressing precision medicine in a world of randomized trials. Expert Review of Precision Medicine and Drug Development, 2018, 3, 225-227.	0.7	0
159	Supportive care. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 709-716.	0.5	0
160	Justification for Separate Consideration of Two Broad Categories of Cancer Patient Use of Complementary Medicine. Society for Integrative Oncology, 2007, 05, 50.	0.7	0
161	Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer. F1000 Medicine Reports, 2010, 2, .	2.9	0
162	Translational Cancer Research Involving Molecularly Defined Targets: Issues in the Development of Effective Therapeutics. , 2014, , 687-696.		0

#	ARTICLE	IF	CITATIONS
163	Supportive care. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2002, 20, 627-32.	0.5	0
164	Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (> 1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications. <i>Cancer Investigation</i> , 2005, 23, 33-5.	1.3	0
165	The role of intraperitoneal chemotherapy in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 809-10.	0.3	0
166	Risk of cervical cancer after HPV vaccination. <i>Current Pharmaceutical Design</i> , 2013, 19, 1488-9.	1.9	0
167	Precision medicine and the rapidly approaching future of cancer management. <i>American Journal of Managed Care</i> , 2012, 18, SP207-8, cover.	1.1	0
168	Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 224-226.	2.5	0
169	Clinical response versus clinical benefit in oncology: not necessarily equivalent terms. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 243-244.	2.5	0